Analysis of solid tumor mutation profiles in liquid biopsy.

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Liquid biopsy offers a less invasive alternative to traditional tumor biopsies.
• It is valuable for cancer prognosis, treatment selection, and monitoring disease progression.

Purpose of the Study:

• To evaluate the concordance between tumor and plasma DNA mutation status.
• To assess the correlation between baseline circulating tumor DNA (ctDNA) levels and patient survival outcomes.

Main Methods:

• Matched tumor and plasma samples from 180 cancer patients (mostly early-stage) were analyzed.
• Tumor profiling used next-generation sequencing (NGS) or qPCR; plasma ctDNA was queried using ddPCR or NGS.

Main Results:

• Tumor-plasma concordance was 82% in advanced stages and 32% in early stages.
• Baseline ctDNA levels stratified patients into distinct survival groups: high ctDNA (poor outcome), undetectable ctDNA (good outcome), and low ctDNA (ambiguous outcome).

Conclusions:

• Liquid biopsy, particularly ctDNA analysis, is a powerful tool for cancer patient management.
• ctDNA levels provide valuable prognostic information and can guide therapeutic decisions across various cancer stages.